Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
July 22, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
June 12, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
June 11, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
June 10, 2024 16:10 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 24, 2024 08:01 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
May 20, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
May 15, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation protein-αAnnounced the in-licensing of a...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
May 03, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
May 02, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
April 30, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...